EUCTR2021-003751-42-IT进行中（未招募）1 期
Randomized phase III clinical trial of Neo-Adjuvant Intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve vesical neoplasms. - n.a.
IRCCS ISTITUTO CLINICO HUMANITAS0 个研究点目标入组 160 人开始时间: 2021年10月22日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male and females, age >18 years old
- •- Primary clinical” diagnosis of urinary bladder cancer and secondary recurrent untreated bladder cancer. The clinical diagnosis will be based on the combination of imaging (ultrasound, CT and MRI), flexible cystoscopy with NBI in out-patients regimen, and urine cytology assessment
- •- Urine cytology negative or positive
- •- Treatment naïve vesical neoplasm at time of enrollment
- •- Eastern Cooperative Oncology Group (ECOG) performance status < 2
- •- Multiple lesions with at least one lesion not smaller than 1 cm as diagnosed through cystoscopy
- •- Negative urinoculture at the beginning of neoadjuvant treatment
- •- Signed informed consent according to ICH/EU GCP, and national/local regulations. All patients have to provide written informed consent before study entry and all phases of this study will be in compliance with the Declaration of Helsinki.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •- Known hypersensitivity to MMC or any of its constituents
- •- Major surgery, other than diagnostic surgery
- •- Previous or concomitant cancer of the upper urinary tract or the prostatic urethra
- •- Previous (within the last 3 years) or current malignancies at other sites, except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri
- •- Presence of significant urologic disease (urethral stricture or hypospadias) interfering with intravesical therapy
- •- Pregnancy and breastfeeding status
- •- Current enrolment or participation in another therapeutic clinical trial within 4 weeks preceding treatment start
- •- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator
- •- Treated with immunomodulatory agents (including cortisone treatment) at time of enrollment or in the two months before enrollment
- •- Treated with antibiotics at time of enrollment or during the month before enrollment
- •- Positive history of sexually transmitted diseases
- •- Suffering from an ongoing or recent (during the three months before enrollment) urinary infection
- •- Suffering from chronic intestinal inflammation
- •Due to the genotoxic potential of mitomycin, it is suggested to a man looking for offspring, during treatment and up to 6 months later to stock the sperm before the start of therapy due to the possibility of irreversible infertility caused by therapy.
研究者
相似试验
尚未招募
3 期
Comparison of chemotherapy after surgery versus surgery alone in non-metastatic, High risk soft tissue sarcoma.CTRI/2022/10/046672Tata Memorial Hospital
进行中（未招募）
不适用
Phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative breast cancer. - NEO-ZOTACEUCTR2009-016932-11-NLBOOG Study Center B.V
已完成
3 期
Phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with large resectable or locally advanced HER2-negative breast cancer.10006291Breast cancerNL-OMON34755BOOG Study Center B.V250
招募中
3 期
JCOG2102: Randomized phase III trial of Neo-adjuvant and adjuvant chemotherapy vs Adjuvant Chemotherapy alone for LocalizEd Soft tissue SarcomaJPRN-jRCTs031220446TANAKA Kazuhiro224
招募中
不适用
Randomized Phase III Trial of the need for adjuvant chemotherapy in stage I epithelial ovarian cancer after comprehensive staging surgeryKCT0005869The Catholic University of Korea, Seoul St. Mary's Hospital360